SAN FRANCISCO, CA -- (Marketwired) -- 09/24/15 -- Vista Partners announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX") (OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, and maintains its twelve-month price target of $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in 2015 and Phase 2 data due on SGX942, the Company's clinical candidate for the treatment of Oral Mucositis, due by the fourth quarter of 2015. Mucositis affects approximately 500,000 people in the US per year and occurs in 40% of patients receiving chemotherapy." Mr. Silver goes on to state, "The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with: Emergent BioSolutions (NYSE: EBS) ($1.2B mkt cap.) & SciClone Pharmaceuticals (NASDAQ: SCLN) ($364M mkt cap.)." Mr. Silver concludes, "The Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018."
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista's mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.